ALIM Stock Summary and Trading Ideas (Alimera Sciences | NASDAQ:ALIM)

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Alimera Sciences trades on the NASDAQ stock market under the symbol ALIM.

As of April 19, 2024, ALIM stock price declined to $3.34 with 48,039 million shares trading.

ALIM has a market cap of $174.86 million. This is considered a Micro Cap stock.

Last quarter Alimera Sciences reported $26 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.07.

In the last 3 years, ALIM stock traded as high as $11.48 and as low as $1.30.

The top ETF exchange traded funds that ALIM belongs to (by Net Assets): VXF, VTI.

ALIM has outperformed the market in the last year with a return of +60.8%, while the SPY ETF gained +21.2%. However, in the most recent history, ALIM shares have underperformed the stock market with its stock returning -15.2% in the last 3 month period and -13.2% for the last 2 week period, while SPY has returned +3.0% and -4.5%, respectively.

ALIM support price is $3.28 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALIM stock will trade within this expected range on the day.